209 related articles for article (PubMed ID: 18458135)
1. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
Perkhofer S; Locher M; Cuenca-Estrella M; Rüchel R; Würzner R; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2008 Jul; 52(7):2636-8. PubMed ID: 18458135
[TBL] [Abstract][Full Text] [Related]
2. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes.
Galgóczy L; Lukács G; Nyilasi I; Papp T; Vágvölgyi C
Acta Biol Hung; 2010 Sep; 61(3):356-65. PubMed ID: 20724281
[TBL] [Abstract][Full Text] [Related]
3. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes.
Gil-Lamaignere C; Hess R; Salvenmoser S; Heyn K; Kappe R; Müller FM
J Antimicrob Chemother; 2005 Jun; 55(6):1016-9. PubMed ID: 15883179
[TBL] [Abstract][Full Text] [Related]
4. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
5. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes.
Simitsopoulou M; Roilides E; Maloukou A; Gil-Lamaignere C; Walsh TJ
Mycoses; 2008 Mar; 51(2):147-54. PubMed ID: 18254752
[TBL] [Abstract][Full Text] [Related]
6. Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment.
Maurer E; Hörtnagl C; Lackner M; Grässle D; Naschberger V; Moser P; Segal E; Semis M; Lass-Flörl C; Binder U
Med Mycol; 2019 Apr; 57(3):351-362. PubMed ID: 29924357
[TBL] [Abstract][Full Text] [Related]
7. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.
Ben-Ami R; Lewis RE; Tarrand J; Leventakos K; Kontoyiannis DP
Antimicrob Agents Chemother; 2010 Jan; 54(1):484-90. PubMed ID: 19858263
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.
Rodríguez MM; Serena C; Mariné M; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3786-8. PubMed ID: 18694953
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
Spreghini E; Orlando F; Giannini D; Barchiesi F
J Antimicrob Chemother; 2010 Oct; 65(10):2158-63. PubMed ID: 20667887
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.
Salas V; Pastor FJ; Calvo E; Alvarez E; Sutton DA; Mayayo E; Fothergill AW; Rinaldi MG; Guarro J
Antimicrob Agents Chemother; 2012 May; 56(5):2246-50. PubMed ID: 22290952
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
12. Posaconazole prophylaxis in experimental systemic zygomycosis.
Barchiesi F; Spreghini E; Santinelli A; Fothergill AW; Pisa E; Giannini D; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2007 Jan; 51(1):73-7. PubMed ID: 17060525
[TBL] [Abstract][Full Text] [Related]
13. A Revised Species Concept for Opportunistic
Wagner L; de Hoog S; Alastruey-Izquierdo A; Voigt K; Kurzai O; Walther G
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182532
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.
Luo G; Gebremariam T; Lee H; French SW; Wiederhold NP; Patterson TF; Filler SG; Ibrahim AS
Antimicrob Agents Chemother; 2013 Jul; 57(7):3340-7. PubMed ID: 23650163
[TBL] [Abstract][Full Text] [Related]
15. Frequency of occurrence, seasonal variation and antifungal susceptibility of opportunistic Mucorales isolated from hospital soils in Iran.
Vaezi A; Walther G; Kurzai O; Mahdi D; Dadashzadeh M; Nasri E; Diba K; Badali H; Fakhim H
Mycoses; 2021 Jul; 64(7):780-787. PubMed ID: 33835599
[TBL] [Abstract][Full Text] [Related]
16. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
Alastruey-Izquierdo A; Castelli MV; Cuesta I; Monzon A; Cuenca-Estrella M; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2009 Apr; 53(4):1686-9. PubMed ID: 19171801
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.
Lewis RE; Ben-Ami R; Best L; Albert N; Walsh TJ; Kontoyiannis DP
J Infect Dis; 2013 Mar; 207(5):834-41. PubMed ID: 23242544
[TBL] [Abstract][Full Text] [Related]
18. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.
Espinel-Ingroff A; Chakrabarti A; Chowdhary A; Cordoba S; Dannaoui E; Dufresne P; Fothergill A; Ghannoum M; Gonzalez GM; Guarro J; Kidd S; Lass-Flörl C; Meis JF; Pelaez T; Tortorano AM; Turnidge J
Antimicrob Agents Chemother; 2015 Mar; 59(3):1745-50. PubMed ID: 25583714
[TBL] [Abstract][Full Text] [Related]
19. Drug combinations against Mucor irregularis in vitro.
Zhang S; Li R; Yu J
Antimicrob Agents Chemother; 2013 Jul; 57(7):3395-7. PubMed ID: 23587956
[TBL] [Abstract][Full Text] [Related]
20. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
Dannaoui E; Schwarz P; Lortholary O
Antimicrob Agents Chemother; 2009 Aug; 53(8):3549-51. PubMed ID: 19451295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
